Alexion Pharmaceuticals, Inc.
Clinical trials sponsored by Alexion Pharmaceuticals, Inc., explained in plain language.
A biopharmaceutical company focused on rare diseases, now part of AstraZeneca.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for rare autoimmune disease: eculizumab trial targets relapses Results expected Dec 2026 (estimated)
- New hope for kids with rare Muscle-Weakening disease Results expected Dec 2026 (estimated)
- New drug ALXN2230 gets first human safety check Results expected Dec 2026 (estimated)
- New drug combo aims to boost red blood cells in kids with rare blood disorder Results expected May 2027 (estimated)
- New drug ravulizumab aims to control rare blood disorder aHUS Results expected Jun 2027 (estimated) May already have reported ↗